Flexibility and choice starts now!
Whether using the FreeStyle Libre 3 Plus or the Eversense 365 CGM, twiist integrates glucose data seamlessly for a unified, streamlined experience.
Sequel is working on adhesive options for on-body wear. Alternative adhesive options are available through third-party providers.
The twiist Automated Insulin Delivery (AID) System Powered by Tidepool
Introducing a first-of-its-kind technology to help your patients manage their type 1 diabetes their way, with unmatched personalization.1,3-7 The pairing of twiist with the FreeStyle Libre 3 Plus sensor or Eversense 365 CGM allows patients to discreetly manage their insulin delivery and monitor their glucose with app-based control through an iPhone or Apple watch.
Innovation that can help your patients think less about diabetes management.
The twiist AID System is committed to expanding choice for people with diabetes, empowering them with more options to manage their health with confidence. We're thrilled that this journey began with the FreeStyle Libre 3 Plus sensor and has expanded to include Eversense 365 CGM.
.png)
Sequel is working on adhesive options for on-body wear. Alternative adhesive options are available through third-party providers.
Sequel is working on adhesive options for on-body wear. Alternative adhesive options are available through third-party providers.
Expanding Choice & Compatibility
Automatically fine-tunes insulin delivery every 5 minutes to meet user-specified correction target. As AID systems evolve, integrated CGMs (iCGMs) like the FreeStyle Libre 3 Plus sensor and Eversense 365 CGM ensure that people with diabetes have the flexibility to choose the sensor that best fits their lifestyle, needs, and insurance coverage. This empowers users with greater control and personalization in their diabetes management.
Advancing Innovation & Interoperability
The iCGM ecosystem is rapidly advancing, with continuous improvements in accuracy, wear time, and integration capabilities. By embracing an iCGM approach, twiist will help drive innovation, support broader adoption, and ensure our AID system remains at the cutting edge of T1D management technology.
Learn More
Sequel is working on adhesive options for on-body wear. Alternative adhesive options are available through third-party providers.
Frequently Asked Questions
Find answers to common questions about iiSure™ sound wave technology and the twiist™ AID System.
Most people pay $0 the 1st month for the twiist™ AID System and no more than $50 each month after that.*
Please follow this link www.twiist.com/discover-twiist to learn more about twiist, what to expect while getting started, and how to connect with a twiist representative!
We continue to work to gain access across all types of insurance including different Medicare and Medicaid plans. Patients should reach out to their specific plan for coverage info.
There is no contract obligation. People living with type 1 diabetes can try twiist without the four-year commitment required by many traditional AID systems, but with the flexibility to manage their diabetes on their terms. Additionally, if your patients are using an AID system that is in existing warranty, they do not need to wait until their current warranty is up to try twiist.
We are currently available in the U.S. only. Our ultimate goal is to make this innovative technology available to people worldwide. We're already taking steps to expand twiist availability beyond the U.S. Regulatory approval and reimbursement vary by region; therefore, we don't have a timeline for international availability yet. Stay tuned by following our page or visiting twiist.com for updates!
Have more questions?
Reach out to our clinical team for detailed information.
Begin offering flexibility and choice
Bring the power of the twiist AID System to your patients today!
.webp)
MAT-1048 Ver 1.0 05/26
.svg)
Personalized Diabetes Control
INDICATIONS FOR USE
The twiist™ Automated Insulin Delivery (AID) system is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin, ages six and above. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The twiist system is intended for single patient, home use and requires a prescription.
The twiist Loop algorithm, is intended for use with compatible integrated continuous glucose monitors (iCGM) and the twiist alternate controller enabled (ACE) insulin infusion pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend, and with the user’s confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds. The twiist Loop algorithm is intended for the management of type 1 diabetes mellitus in persons six years of age and greater. The twiist Loop algorithm is intended for single patient use and requires a prescription.
The twiist Automated Insulin Delivery System includes a simple bolus calculator available when Loop is off. It is indicated for use for aiding the user in determining the bolus insulin dosage for management of diabetes mellitus based on consumed carbohydrates, operator entered blood glucose, insulin sensitivity, insulin to carbohydrate ratio, target glucose values, and current insulin on board.
CONTRAINDICATIONS
The twiist automated insulin delivery system is not intended for anyone unable or unwilling to:
- Test blood glucose (BG) levels as recommended by their healthcare provider.
- Maintain sufficient diabetes selfcare skills.
- See their healthcare provider regularly.
- Demonstrate adequate carbohydrate-counting skills (preferred, not required).
Product not yet available outside of the U.S.
The user must not:
- Have difficulty seeing.
- Have difficulty hearing.
- Have deficient cognitive capabilities.
- Have physical impairments that would make operating the pump or iPhone difficult.
- Sequel Med Tech - twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide.
- Calculation based on a comparison of the following IFUs. The following reported 1 U/hr basal rate: Sequel Med Tech - twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide; lnsulet - Omnipod 5 Automated Insulin Delivery System User Guide; Medtronic - MiniMed 780G system User Guide; Beta Bionics - iLet Bionic Pancreas System User Guide. The following reported 2 U/hr basal rate: Tandem Diabetes Care - t:slim X2 Insulin Pump User Guide; Tandem Diabetes Care - Tandem Mobi System User Guide.
- lnsulet - Omnipod 5 Automated Insulin Delivery System User Guide.
- Medtronic - MiniMed 780G system User Guide.
- Beta Bionics - iLet Bionic Pancreas System User Guide.
- Tandem Diabetes Care - t:slim X2 Insulin Pump User Guide.
- Tandem Diabetes Care - Tandem Mobi System User Guide.
- Lum JW, et al. A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technol Ther. 2021;23(5):367-375.
- Wong JJ, et al. Psychosocial Effects of the Loop Open-Source Automated Insulin Delivery System. J Diabetes Sci Technol. 2023;17(6):1440-1447.
- Butterfield RD, et al. Performance of a Continuous Subcutaneous Insulin Infusion (CSII) Pump With Acoustic Volume and Flow Sensing in Simulated High-Consequence Situations. IEEE Open J Eng Med Biol. 2024;5:593-599.
- Klonoff DC, et al. Time to Moderate and Severe Hyperglycemia and Ketonemia Following an Insulin Pump Occlusion. J Diabetes Sci Technol 2024.
- Snow K, Aleppo G, Mitri J. (2026, March). Early Clinical Performance in the twiist™ AID System. [Poster Presentation] ATTD, Barcelona, Spain.
- Study Design: Approved by the Institutional Review Board of the JAEB Center for Health Research (ClinicalTrials.gov Identifier: NCT03838900), Wong et al conducted a prospective, observational, real-world study including a subset of 239 adults with T1D to evaluate the psychosocial and quality of life outcomes of using DIY Loop. Patients initiated the DIY Loop either on their own, or with community-developed resources, and used the DIY Loop algorithm with a non-twiist insulin pump over 3 months.
*The twiist™ Savings Program is available to individuals with a valid prescription and commercial insurance that covers twiist. Eligible participants can receive a Starter Kit for $0 and pay no more than $50 for Refill Kits. This offer is not valid for individuals enrolled in Medicare, Medicaid, or any other federal or state programs, or for cash-paying patients and non-covered claims. It is available only in the U.S. and is not valid in Puerto Rico, U.S. Territories, or where prohibited by law. While most commercially insured participants qualify for the $50 Refill Kit offer, those with high-deductible plans who haven't met their deductible may pay more than $50 per Refill Kit until their deductible is met. The maximum benefit is $200 per Refill Kit for covered claims. Terms are subject to change. Call us at 1-877-489-4478 or contact your insurance provider to confirm
For full FreeStyle Libre 3 Plus sensor safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. The Eversense 365®Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. For important safety information, see bit.ly/eversensesafety
“twiist,” “iiSure,” and the twiist logo are licensed trademarks of Sequel Med Tech, LLC. “Tidepool” and the Tidepool logo are trademarks of Tidepool Project, a fully-qualified 501(c)(3) nonprofit organization. © 2026 Sequel Med Tech, LLC. All rights reserved.